Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 14/20 | 0.88 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | PGR | P06401 | 3/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.49 |
| ▸ | SMO | Q99835 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1361781 | 0.89 | NR3C1 (0.90) | NR3C1PGR | |
| SCHEMBL1361991 | 0.84 | NR3C1 (0.81) | NR3C1MAPK1PGRSMO | |
| SCHEMBL1363186 | 0.84 | NR3C1 (0.81) | NR3C1MAPK1PGRSMO | |
| SCHEMBL22806014 | 0.82 | NR3C1 (0.78) | NR3C1MAPK1PGRSMO | |
| SCHEMBL27724613 | 0.80 | NR3C1 (0.74) | NR3C1PGRSMO | |
| SCHEMBL3853770 | 0.80 | NR3C1 (0.74) | NR3C1PGR | |
| SCHEMBL1362717 | 0.79 | NR3C1 (0.69) | NR3C1PGR | |
| SCHEMBL1363827 | 0.79 | NR3C1 (0.72) | NR3C1PGRSMO | |
| SCHEMBL1362437 | 0.77 | NR3C1 (0.69) | NR3C1PGR | |
| SCHEMBL1362432 | 0.77 | NR3C1 (0.69) | NR3C1PGRCYP11B2SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094692-B1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2012-11-28 | — | — | EP | disclosed |
| US-8067447-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100076014-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-25 | — | — | US | disclosed |
| EP-2094692-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF | Brystol-Myers Squibb Company (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008057856-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076014-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFRKB, NFKBIA, NFKB1 | NR3C1 11/4885MAPK1 277/4885PGR 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.